Profile: Ranbaxy Laboratories Ltd (RBXLY.PK)
Ranbaxy Laboratories Limited, incorporated on June 16, 1961, is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40 countries, products sold in over 150 countries, manufacturing facilities in approximately eight countries. The Company owns manufacturing facilities in seven countries, namely India, the United States of America, Ireland, Malaysia, Nigeria, Romania and South Africa. The Company’s markets include the United States of America, India, Europe, Russia/ CIS and South Africa. The research and development activities of the Company are principally carried out at its facilities in Gurgaon, near New Delhi, India.
The Company manufactures and market over 500 molecules and their combinations in multiple dosage forms, catering to patient needs in various therapies. These include Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology. The company’s over the counter brands include REVITAL, REVITAL LIQUID, REVITAL WOMAN, REVITAL SENIOR, REVITALITE, VOLINI GEL, VOLINI SPRAY, VOLINI ACTIV GEL, CHERICOF COUGH SYRUP, PEPFIZ, GARLIC PEARLS and GESDYP.
Ranbaxy Laboratories Ltd
Plot 90, Sector 32
Company Web Links
- INDIA PRESS-Ranbaxy may sell Biovel, exit vaccine business-Business Standard
- India's Ranbaxy posts loss in Sept qtr due to forex charges
- Suspected human hair in tablet cited in FDA's Ranbaxy import ban
- UPDATE 3-Third FDA ban on India's Ranbaxy threatens its U.S. sales
- Ranbaxy says not received any FDA communication on import alert